Kimura M, Inoue H, Uchitubo T, Kojima H, Okabayashi I
Department of Pharmacy, Kyoto University Hospital Faculty of Medicine, Kyoto University, Japan.
Yakugaku Zasshi. 1993 Jun;113(6):454-9. doi: 10.1248/yakushi1947.113.6_454.
In order to elucidate the structure-activity relationship between the antitumor activity and the molecular structure of novel DNA-intercalator acridine derivatives (1a-g and 2a-i in Chart 1), DNA-binding properties (intercalation) of these acridines were examined by quenching in the fluorescence of the ethidium-DNA complex. The mechanism of quenching is caused by the displacement of DNA-bound ethidium by a second DNA binding ligand, acridines. The concentration (C50 value) of acridine necessary to reduce the initial fluorescence of DNA-bound ethidium by 50% showed a good correlation with their antitumor activities. The quenching of fluorescence for acridines was examined using amsacrine (AMSA) as a typical standard of the second DNA-bound ligand, and calf thymus DNA with an apparent site size of two base pair. Some of the acridine derivatives showed more potent quenching of fluorescence than amsacrine (AMSA).
为阐明新型DNA嵌入剂吖啶衍生物(图1中的1a - g和2a - i)的抗肿瘤活性与分子结构之间的构效关系,通过猝灭溴化乙锭 - DNA复合物的荧光来检测这些吖啶的DNA结合特性(嵌入)。猝灭机制是由第二种DNA结合配体吖啶取代与DNA结合的溴化乙锭引起的。将与DNA结合的溴化乙锭的初始荧光降低50%所需的吖啶浓度(C50值)与其抗肿瘤活性具有良好的相关性。以安吖啶(AMSA)作为第二种与DNA结合配体的典型标准,使用表观位点大小为两个碱基对的小牛胸腺DNA来检测吖啶的荧光猝灭情况。一些吖啶衍生物表现出比安吖啶(AMSA)更强的荧光猝灭能力。